首页> 外文期刊>Frontiers in Medicine >Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human
【24h】

Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human

机译:建立世界卫生组织关于人类血浆XII的第一个国际标准

获取原文
       

摘要

Until recently, the role of factor XII (FXII) in hemostasis was not considered to be important since patients with FXII deficiency do not present with bleeding. The activation of FXII by agents including mast cells and platelet polyphosphates suggests that it may have a role in thrombogenesis. The inhibition of FXII therefore presents an option for antithrombotic therapy, and antibodies and inhibitors are already in development. Assays for FXII will be required to support these technologies, and an international standard (IS) for FXII would be useful for the development of these methods and for the clinical monitoring of patients. The purpose of this study was to develop an IS for FXII, with values for functional activity (FXII:C) and antigen (FXII:Ag). Double-spun normal plasma was pooled, filled into siliconized glass ampoules, and freeze-dried to prepare the candidate material. Data from 20 laboratories using the one-stage clotting assay were used to assign the functional activity value in units (u). The antigen value was calculated using data from eight laboratories that carried out antigen assays. Each laboratory was requested to collect two local normal plasma pools. Units of activity and antigen were calculated relative to these pools, as is usual for new coagulation factor analytes. The amount of activity or antigen in 1 ml of normal plasma from each pool was taken to be 1 unit. A total of 566 donors were used across the pools for the FXII:C study and 216 donors for the FXII:Ag study. The overall geometric mean per ampoule for FXII:C was 0.86 u and for FXII:Ag was 0.80 u. The inter-laboratory variation was 10 and 11%, respectively (expressed as the geometric coefficient of variation). Based on these data, the candidate was deemed suitable for use as an IS for FXII. In 2017, the candidate was established by the World Health Organization (WHO) Expert Committee on Biological Standardization as the WHO first IS for blood coagulation FXII, Plasma (National Institute for Biological Standards and Control code 15/180). The values assigned were 0.86 international units (IU) of functional activity (FXII:C) per ampoule and 0.80 IU/ampoule of antigen (FXII:Ag).
机译:直到最近,由于FXII缺乏症患者没有出血,因此XII因子(FXII)在止血中的作用还不重要。包括肥大细胞和血小板多磷酸盐在内的试剂对FXII的激活表明它可能在血栓形成中起作用。因此,FXII的抑制为抗血栓治疗提供了一种选择,并且抗体和抑制剂已经在开发中。 FXII的检测将需要支持这些技术,而FXII的国际标准(IS)将对开发这些方法和对患者进行临床监测很有用。这项研究的目的是开发一种用于FXII的IS,具有功能活性(FXII:C)和抗原(FXII:Ag)的值。合并双旋转正常血浆,填充到硅化玻璃安瓿瓶中,冷冻干燥以制备候选材料。使用一级凝结测定法从20个实验室获得的数据用于分配功能活性值(单位:u)。使用来自进行抗原测定的八个实验室的数据来计算抗原值。每个实验室被要求收集两个局部正常血浆池。与新的凝血因子分析物一样,相对于这些库计算活性和抗原的单位。来自每个池的1微升正常血浆中的活性或抗原的量取为1个单位。总共566个供体用于FXII:C研究,216个供体用于FXII:Ag研究。 FXII:C的每个安瓿瓶的总体几何平均数为0.86 u,而FXII:Ag的总几何平均数为0.80 u。实验室间的差异分别为10%和11%(表示为几何差异系数)。根据这些数据,该候选人被认为适合用作FXII的IS。 2017年,该候选人由世界卫生组织(WHO)生物标准化专家委员会确定为WHO血浆FXII血浆FXII的首个IS(国家生物标准与控制研究所代码15/180)。分配的值为每安瓿0.86国际单位(IU)的功能活性(FXII:C)和0.80IU /安瓿的抗原(FXII:Ag)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号